These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29499075)

  • 1. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
    Dall'Era MA; Lo MJ; Chen J; Cress R; Hamilton AS
    Cancer; 2018 May; 124(9):1921-1928. PubMed ID: 29499075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
    Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
    Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
    Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
    Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
    Yang DD; Mahal BA; Muralidhar V; Boldbaatar N; Labe SA; Nezolosky MD; Vastola ME; Beard CJ; Martin NE; Mouw KW; Orio PF; King MT; Nguyen PL
    Cancer; 2017 Dec; 123(24):4832-4840. PubMed ID: 28832984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
    Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
    Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Patel DN; Jha S; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Chapin BF; Freedland SJ
    Int J Urol; 2018 Dec; 25(12):998-1004. PubMed ID: 30253446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer.
    Kim AH; Konety B; Chen Z; Schumacher F; Kutikov A; Smaldone M; Abouassaly R; Khanna A; Kim SP
    Urology; 2018 Oct; 120():173-179. PubMed ID: 29990574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and secondary interventions following treatment for locally-advanced prostate cancer.
    Sussman R; Carvalho FLF; Harbin A; Zheng C; Lynch JH; Stamatakis L; Hwang J; Williams SB; Hu JC; Kowalczyk KJ
    Can J Urol; 2018 Oct; 25(5):9516-9524. PubMed ID: 30281010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
    JAMA; 2008 Jul; 300(2):173-81. PubMed ID: 18612114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
    Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
    Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.